Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Maravai Lifesciences Holdings Inc's Business Segments
Maravai Lifesciences Holdings Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
2
Largest Segment
TriLink
Total Revenue
$ 51
Regions Reported
4
Revenue Share by Reportable Segment - Q2 FY2026
- TriLink67.4%
- Cygnus32.6%
Revenue by Reportable Segment - Q2 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| TriLink | $ 35 | 67.4% |
| Cygnus | $ 17 | 32.6% |
Revenue Share by Region - Q2 FY2026
- North America60.8%
- EMEA20.3%
- Asia Pacific18.1%
- Latin and Central America0.8%
Revenue by Geographic Region - Q2 FY2026
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| North America | $ 31 | 60.8% |
| EMEA | $ 10 | 20.3% |
| Asia Pacific | $ 9 | 18.1% |
1 more regions available
Sign in to unlock the full Maravai Lifesciences Holdings Inc dataset.
Description of Maravai Lifesciences Holdings Inc
Maravai Lifesciences Holdings Inc is a global life sciences company that develops and provides critical products and services to the biopharmaceutical, diagnostic, and broader life sciences industries. The company was founded in 2014 and is headquartered in San Diego, California, United States.
The company operates through two business segments: Contract Development & Manufacturing Organization (CDMO) and Life Sciences.
The CDMO segment provides development and manufacturing services for gene therapy and vaccine products, as well as diagnostic and other biologics products. Its services include process development, cell line development, clinical and commercial manufacture, and testing and analytics.
The Life Sciences segment includes three business units: Genomics, Diagnostics, and Protein Sciences. The Genomics unit provides nucleic acid isolation and purification products, as well as other sample collection and preparation products for genetic sequencing applications. The Diagnostics unit develops and manufactures an array of diagnostic kits and reagents, and also provides custom contract development services. The Protein Sciences unit provides research and diagnostic tools for protein analysis.
Maravai has a global presence, with facilities in the United States, Europe, and Asia-Pacific. The company's clients include leading biopharmaceutical, research, academic and diagnostic organizations.
The company has been experiencing significant growth over the past few years, driven by strong demand for its products and services, as well as its focus on innovation and strategic acquisitions. In September 2020, Maravai completed its initial public offering (IPO), raising $62 billion USD in gross proceeds.
Overall, Maravai Lifesciences Holdings Inc is a highly respected and innovative company in the life sciences industry, dedicated to delivering high-quality, critical products and services to its clients worldwide.
The company operates through two business segments: Contract Development & Manufacturing Organization (CDMO) and Life Sciences.
The CDMO segment provides development and manufacturing services for gene therapy and vaccine products, as well as diagnostic and other biologics products. Its services include process development, cell line development, clinical and commercial manufacture, and testing and analytics.
The Life Sciences segment includes three business units: Genomics, Diagnostics, and Protein Sciences. The Genomics unit provides nucleic acid isolation and purification products, as well as other sample collection and preparation products for genetic sequencing applications. The Diagnostics unit develops and manufactures an array of diagnostic kits and reagents, and also provides custom contract development services. The Protein Sciences unit provides research and diagnostic tools for protein analysis.
Maravai has a global presence, with facilities in the United States, Europe, and Asia-Pacific. The company's clients include leading biopharmaceutical, research, academic and diagnostic organizations.
The company has been experiencing significant growth over the past few years, driven by strong demand for its products and services, as well as its focus on innovation and strategic acquisitions. In September 2020, Maravai completed its initial public offering (IPO), raising $62 billion USD in gross proceeds.
Overall, Maravai Lifesciences Holdings Inc is a highly respected and innovative company in the life sciences industry, dedicated to delivering high-quality, critical products and services to its clients worldwide.
Maravai Lifesciences Holdings Inc. is a prominent player in the life sciences industry, dedicated to delivering innovative products and services across a variety of domains. Its operations are structured into three primary business segments: Life Sciences, Diagnostics, and Therapeutics. Each segment encompasses a diverse portfolio tailored to meet the evolving needs of researchers, clinicians, and biopharmaceutical developers.
Life Sciences Segment
The Life Sciences segment focuses on providing essential tools and technologies for the research and development of novel biopharmaceuticals and vaccines. Key offerings within this segment include:
1. Biologics: Maravai excels in creating a wide array of biologics, which include antibodies, recombinant proteins, and enzymes. These biologics are critical for applications in areas such as immune-oncology—targeting and destroying cancer cells—regenerative medicine, and combatting infectious diseases.
2. Nucleic Acid Production: Utilizing proprietary technologies, Maravai offers custom nucleic acid production services. This includes the synthesis of a variety of nucleic acids such as mRNA, siRNA, and plasmid DNA. Their ability to produce high-quality nucleic acids in large quantities supports diverse applications, including RNA interference techniques and CRISPR gene-editing workflows.
3. Sample Preparation: The company provides robust sample preparation solutions essential for genomics and proteomics research. This product line features bead-based kits, magnetic beads, and microfluidic cartridges designed to optimize workflows in nucleic acid extraction, purification, and analysis.
Diagnostics Segment
The Diagnostics segment encompasses a broad range of products and services utilized in clinical diagnostics, drug development, and medical research:
1. Clinical Diagnostics: Maravai offers comprehensive solutions for clinical diagnostics, specializing in applications related to infectious diseases, oncology, and hematopathology. Their offerings include specialized reagents, control materials, and assays that ensure accurate and reliable diagnostic results.
2. Drug Development: Within this space, Maravai provides essential tools for drug developers, including monoclonal antibodies, recombinant proteins, and enzymes. These products facilitate the research and production of therapeutics, aiding in the development of effective treatments.
3. Medical Research: The company supports medical research with a variety of products including RNA and DNA extraction kits, quantitative PCR (qPCR) and reverse transcription quantitative PCR (RT-qPCR) reagents, and electrophoresis instruments. These tools are vital for genetic analysis, enabling researchers to explore disease mechanisms and develop therapeutic strategies.
Therapeutics Segment
The Therapeutics segment is dedicated to advancing therapies in cell and gene therapy, playing a transformative role in treating genetic and acquired diseases:
1. Cell and Gene Therapy: Maravai is at the forefront of the cell and gene therapy landscape, providing essential products such as lentiviral vectors, adeno-associated virus (AAV) vectors, and plasmid DNA. These components are pivotal for gene delivery mechanisms utilized in therapeutic applications.
2. Culturing and Transfection: To support cell-based therapies, Maravai offers a variety of products related to cell culturing and transfection. This includes specialized media, growth supplements, and transfection reagents that help facilitate efficient delivery of nucleic acids into cells.
3. Stem Cell Research: The company also caters to the stem cell research community by providing products essential for stem cell culture. This includes custom culture media, supplements conducive for growth, and differentiation kits that allow researchers to direct stem cell differentiation into specific cell types.
Conclusion
Overall, Maravai Lifesciences Holdings Inc. represents a comprehensive and high-quality source for advanced life sciences products and services. Its commitment to innovation, customer focus, and robust technical expertise positions it effectively within the competitive landscape of the life sciences market. The companys ability to cater to a wide array of scientific and clinical applications ensures it remains a critical partner in the ongoing advancement of biopharmaceutical development and medical research.
Life Sciences Segment
The Life Sciences segment focuses on providing essential tools and technologies for the research and development of novel biopharmaceuticals and vaccines. Key offerings within this segment include:
1. Biologics: Maravai excels in creating a wide array of biologics, which include antibodies, recombinant proteins, and enzymes. These biologics are critical for applications in areas such as immune-oncology—targeting and destroying cancer cells—regenerative medicine, and combatting infectious diseases.
2. Nucleic Acid Production: Utilizing proprietary technologies, Maravai offers custom nucleic acid production services. This includes the synthesis of a variety of nucleic acids such as mRNA, siRNA, and plasmid DNA. Their ability to produce high-quality nucleic acids in large quantities supports diverse applications, including RNA interference techniques and CRISPR gene-editing workflows.
3. Sample Preparation: The company provides robust sample preparation solutions essential for genomics and proteomics research. This product line features bead-based kits, magnetic beads, and microfluidic cartridges designed to optimize workflows in nucleic acid extraction, purification, and analysis.
Diagnostics Segment
The Diagnostics segment encompasses a broad range of products and services utilized in clinical diagnostics, drug development, and medical research:
1. Clinical Diagnostics: Maravai offers comprehensive solutions for clinical diagnostics, specializing in applications related to infectious diseases, oncology, and hematopathology. Their offerings include specialized reagents, control materials, and assays that ensure accurate and reliable diagnostic results.
2. Drug Development: Within this space, Maravai provides essential tools for drug developers, including monoclonal antibodies, recombinant proteins, and enzymes. These products facilitate the research and production of therapeutics, aiding in the development of effective treatments.
3. Medical Research: The company supports medical research with a variety of products including RNA and DNA extraction kits, quantitative PCR (qPCR) and reverse transcription quantitative PCR (RT-qPCR) reagents, and electrophoresis instruments. These tools are vital for genetic analysis, enabling researchers to explore disease mechanisms and develop therapeutic strategies.
Therapeutics Segment
The Therapeutics segment is dedicated to advancing therapies in cell and gene therapy, playing a transformative role in treating genetic and acquired diseases:
1. Cell and Gene Therapy: Maravai is at the forefront of the cell and gene therapy landscape, providing essential products such as lentiviral vectors, adeno-associated virus (AAV) vectors, and plasmid DNA. These components are pivotal for gene delivery mechanisms utilized in therapeutic applications.
2. Culturing and Transfection: To support cell-based therapies, Maravai offers a variety of products related to cell culturing and transfection. This includes specialized media, growth supplements, and transfection reagents that help facilitate efficient delivery of nucleic acids into cells.
3. Stem Cell Research: The company also caters to the stem cell research community by providing products essential for stem cell culture. This includes custom culture media, supplements conducive for growth, and differentiation kits that allow researchers to direct stem cell differentiation into specific cell types.
Conclusion
Overall, Maravai Lifesciences Holdings Inc. represents a comprehensive and high-quality source for advanced life sciences products and services. Its commitment to innovation, customer focus, and robust technical expertise positions it effectively within the competitive landscape of the life sciences market. The companys ability to cater to a wide array of scientific and clinical applications ensures it remains a critical partner in the ongoing advancement of biopharmaceutical development and medical research.